ResMed slips as Wolfe downgrades on GLP-1 threat from Lilly

ResMed headquarters in San Diego, CA, USA.

JHVEPhoto

ResMed (NYSE:RMD) shares fell Wednesday after Wolfe Research downgraded the MedTech, citing risks to the company’s CPAP (continuous positive airway pressure) device business from a potential label expansion for Eli Lilly’s (NYSE:LLY) GLP-1 agonist tirzepatide.

Wolfe Analyst Mike Polark lowered

Leave a Reply

Your email address will not be published. Required fields are marked *